Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331173 · ClinicalTrials.gov registry record
Clinical Evaluation of Patients With X-linked Retinoschisis
A clinical trial, sponsored by Beacon Therapeutics.
- Completed
- Registry status
- 66
- Enrollment target
NCT02331173: Completed study, sponsored by Beacon Therapeutics.
NCT02331173 is a clinical trial that has completed, run by Beacon Therapeutics. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02331173 has completed, sponsored by Beacon Therapeutics.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.
Interventions
- DRUG Dorzolamide 2% TID or brinzolamide 1% TID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-10 |
What the finished NCT02331173 record still lists
NCT02331173 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dorzolamide 2% TID or brinzolamide 1% TID is the first listed.
NCT02331173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02331173 about?
NCT02331173 is a clinical study titled "Clinical Evaluation of Patients With X-linked Retinoschisis". The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.
What is the current status of trial NCT02331173?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2012-11. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02331173?
The interventions under investigation include: Dorzolamide 2% TID or brinzolamide 1% TID (DRUG).
Who is sponsoring clinical trial NCT02331173?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia